下一代肿瘤学中的神经免疫轴靶向：β2 肾上腺素能阻断逆转生态系统范围耐药的发现与验证

Despite the potential of current cancer immunotherapies, tumor cells frequently evade immune surveillance by forming an immunosuppressive microenvironment, leading to treatment resistance. Current inquiry positions the sympathetic nervous system (SNS) at the forefront of tumor immunology as a critical driver of this immune evasion. This review delineates the cellular pharmacology of SNS-mediated immune regulation across the tumor ecosystem. Operating predominantly through the cyclic adenosine monophosphate-protein kinase A (cAMP-PKA) signaling axis, the SNS engages in bidirectional regulation with immune cells of the tumor microenvironment (TME). Norepinephrine and epinephrine interact with 2 -adrenergic receptors ( 2 -ARs), triggering G-protein dissociation, adenylyl cyclase stimulation, and cAMP generation.

This pharmacological cascade promotes the polarization of macrophages to the M2 phenotype, hinders dendritic cell maturation, impairs natural killer (NK) cell function, fosters the differentiation of regulatory T cells (Tregs), and suppresses the effector activity of CD8 + T cells. Consequently, we evaluate the translational prospects of repurposing -blockers as potent anti-cancer immunomodulators.

Preclinical evidence demonstrates that pharmacological blockade of 2 -AR signaling can reverse these immunosuppressive effects, augmenting intratumoral CD8 + T-cell infiltration and enhancing the efficacy of immune checkpoint inhibitors (ICIs). Ultimately, engineering multimodal combination regimens-guided by multi-omics biomarker stratification-offers a novel trajectory to overcome resistance, restore therapeutic sensitivity, and advance precision cancer immunotherapy.